MNTN, Inc Class A MNTN 深 滬
已收盤 02-06 16:00:00 美东时间
8.04
+0.160
+2.03%
華盛通- 最 高8.19
- 今 開7.90
- 成交量 91.09万股
- 最 低 7.71
- 昨 收 7.88
- 總市值 5.89亿
- 52周最高 32.49
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 7.71
- 委 比 -75.00%
- 總股本 7322.33万
- 歷史最高 32.49
- 量 比 1.17
- 振 幅 6.09%
- 歷史最低 7.71
- 每 手 1
- 風險率 5.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cramer Calls MNTN 'Awful'—But Says To 'Pull The Trigger' On This 'Great Spec'
BW is a great spec on power plant construction, wait for it to drop and then pull the trigger. MNTN is awful, must make money to turn around.
01-15 21:34
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Morgan Stanley Maintains Equal-Weight on MNTN, Lowers Price Target to $20.5
Morgan Stanley analyst Matthew Cost maintains MNTN (NYSE:MNTN) with a Equal-Weight and lowers the price target from $22.5 to $20.5.
01-14 00:27
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
Canaccord Genuity Initiates Coverage On MNTN with Buy Rating, Announces Price Target of $20
Canaccord Genuity analyst Matthew Weber initiates coverage on MNTN (NYSE:MNTN) with a Buy rating and announces Price Target of $20.
2025-12-04 21:41
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
Needham Maintains Buy on MNTN, Lowers Price Target to $18
Needham analyst Laura Martin maintains MNTN (NYSE:MNTN) with a Buy and lowers the price target from $35 to $18.
2025-11-05 19:51
MNTN Q3 EPS $0.08 Beats $0.06 Estimate, Sales $70.023M Miss $70.101M Estimate
MNTN (NYSE:MNTN) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 128.57 percent increase over losses of $(0.28) per share from the same period
2025-11-05 05:23
